9-(N-methyl-L-isoleucine)-cyclosporin A

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
9-(N-methyl-L-isoleucine)-cyclosporin A
Accession Number
DB13068
Type
Small Molecule
Groups
Investigational
Description

9-(N-methyl-L-isoleucine)-cyclosporin A (NIM811) has been used in trials studying the treatment of Chronic Hepatitis C Genotype-1 Relapse.

Structure
Thumb
Synonyms
Not Available
External IDs
NIM811
Categories
UNII
96262S4I14
CAS number
143205-42-9
Weight
Average: 1202.635
Monoisotopic: 1201.841368058
Chemical Formula
C62H111N11O12
InChI Key
RPJPZDVUUKWPGT-FOIHOXPVSA-N
InChI
InChI=1S/C62H111N11O12/c1-25-28-29-40(15)52(75)51-56(79)65-43(27-3)58(81)67(18)33-47(74)71(22)50(39(14)26-2)55(78)66-48(37(10)11)61(84)68(19)44(30-34(4)5)54(77)63-41(16)53(76)64-42(17)57(80)69(20)45(31-35(6)7)59(82)70(21)46(32-36(8)9)60(83)72(23)49(38(12)13)62(85)73(51)24/h25,28,34-46,48-52,75H,26-27,29-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b28-25+/t39-,40+,41-,42+,43-,44-,45-,46-,48-,49-,50-,51-,52+/m0/s1
IUPAC Name
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-24-[(2S)-butan-2-yl]-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone
SMILES
CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC1=O)C(C)C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
6473876
PubChem Substance
347829196
ChemSpider
4976066
BindingDB
50339126
ChEMBL
CHEMBL1688529

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentChronic Hepatitis C Genotype-1 Relapse1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00967 mg/mLALOGPS
logP4.2ALOGPS
logP3.72ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)11.83ChemAxon
pKa (Strongest Basic)-2.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area278.8 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity327.06 m3·mol-1ChemAxon
Polarizability131.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cyclosporins. These are cyclic depsipeptides containing the cyclosporin backbone.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Peptidomimetics
Sub Class
Peptoid-peptide hybrids
Direct Parent
Cyclosporins
Alternative Parents
Oligopeptides / Macrolactams / Alpha amino acids and derivatives / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Secondary alcohols / Lactams / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
Cyclosporin-backbone / Alpha-oligopeptide / Macrolactam / Alpha-amino acid or derivatives / Tertiary carboxylic acid amide / Carboxamide group / Lactam / Secondary alcohol / Secondary carboxylic acid amide / Carboxylic acid derivative
show 12 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 20:37 / Updated on November 02, 2018 07:33